Combination therapy for benign prostatic hyperplasia in the light of clinical guidelines


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article reviews clinical trials on the effectiveness of combination therapy with 5a-reductase inhibitors and a-blockers in men with benign prostatic hyperplasia (BPH). These trials have demonstrated a significant improvement in the symptoms and quality of life in this group of patients. The authors outline main strategies offered by the Russian clinical guidelines for BPH patients.

Full Text

Restricted Access

About the authors

A. Z Vinarov

I.M. Sechenov First MSMU of Minzdrav of Russia (Sechenov University)

Email: avinarov@mail.ru
Dr.Med.Sci., Professor at the Department of Urology

L. G Spivak

I.M. Sechenov First MSMU of Minzdrav of Russia (Sechenov University)

Email: leonid.spivak@gmail.com
Ph.D., Associate Professor at the Department of Urology

A. V Mironov

Medical Department at GlaxoSmithKline

Email: alexey.v.mironov@gsk.com
Ph.D.

References

  1. Farmer R., Clifford J.G. Incidence and prevalence of LUTS/BPH in the UK in the 1990. BJU Int. 2002; 90(Suppl. 2):74.
  2. Loh S.Y., Chin C.M. A demographic profile of patients undergoing transurethral resection of the prostate for benign prostate hyperplasia and presenting in acute urinary retention. BJU. 2002; 89(6):531-533.
  3. Bruskewitz R. Management of symptomatic BPH in the US: who is treatedand how? Eur Urol. 1999;36(Suppl. 3):7-13.
  4. Garraway W.M., Collins G.N., Lee R.J. High prevalence of benign prostatic hypertrophy in the community. Lancet. 1991;338(8765):469-471.
  5. Roth S., Buzeline J.M., Delauche-Cavallier M.C. Correlation between symptomatic improvement as-sessed by Boyarsky and I-PSS symptom scores in patients with benign prostatic hyperplasia (BPH). Eur. Urol. 1996;30(Supp. 2):57.
  6. Гориловский Л.М. Доброкачественная гиперплазия предстательной железы / Под ред. Н. А. Лопаткина. М.: 1997. С. 10-18
  7. Emberton M., Andriole G.L., de la Rosette J. et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology. 2003;61:267-273.
  8. Урология. Российские клинические рекомендации / под ред. Ю.Г. Аляева, П.В. Глыбочко, Д.Ю. Пушкаря. 2017. 544 с.
  9. Roehrborn C.G. et al. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart®) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-nanve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJU Int. 2015;116:450-459.
  10. Emberton M. Patient-led management of BPH: from watchful waiting to self-management of LUTS. Eur Urol Suppls 2006; 5: 704-709.
  11. Siami P., Roehrborn C.G., Barkin J. et al. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart® and Tamsulosin) trial rationale and study design. Contemp Clin Trials. 2007;28:770-779.
  12. Roehrborn C.G., Siami P., Barkin J. et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J. Urol. 2008;179:616-621.
  13. Roehrborn C.G., Siami P., Barkin J. et al. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study. Eur Urol. 2009;55:461-471.
  14. Montorsi F., Henkel T., Geboers A. et al. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study. Int J. Clin Pract. 2010; 64:1042-1051.
  15. Debruyne F., Barkin J., van Erps P., Reis M., Tammela T.L.J., Roehrborn C. Efficacy and safety of long-term treatment with the dual 5a-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol. 2004;46:488-495.
  16. Emberton M., Andriole G.L., de la Rosette J., et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology. 2003;61:267-273.
  17. Emberton M., Fitzpatrick J.M., Garcia-Losa M., Qizilbash N., Djavan B. Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials. BJU Int. 2008;102:981-986.
  18. Auffenberg G.B., Helfand B.T., McVary K.T. Established medical therapy for benign prostatic hyperplasia. Urol Clin North Am. 2009;36: 443-459.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies